Geode Capital Management
BTAI icon

Geode Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

Geode Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$309K Buy
230,168
+24,000
+12% +$39.5K ﹤0.01% 3765
2025
Q4 		$330K Buy
206,168
+80,928
+65% +$167K ﹤0.01% 3735
2025
Q3 		$321K Buy
125,240
+97,058
+344% +$306K ﹤0.01% 3769
2025
Q2 		$51K Buy
28,182
+6,120
+28% +$10.1K ﹤0.01% 4214
2025
Q1 		$44.8K Buy
22,062
+2,564
+13% +$9.57K ﹤0.01% 4219
2024
Q4 		$117K Buy
19,498
+870
+5% +$7.27K ﹤0.01% 4060
2024
Q3 		$182K Buy
18,628
+1,958
+12% +$26.3K ﹤0.01% 3931
2024
Q2 		$341K Sell
16,670
-11,950
-42% -$400K ﹤0.01% 3717
2024
Q1 		$1.29M Buy
28,620
+481
+2% +$22.9K ﹤0.01% 3264
2023
Q4 		$1.33M Buy
28,139
+1,694
+6% +$94.2K ﹤0.01% 3232
2023
Q3 		$1.07M Buy
26,445
+1,154
+5% +$117K ﹤0.01% 3289
2023
Q2 		$2.69M Buy
25,291
+1,345
+6% +$448K ﹤0.01% 3015
2023
Q1 		$7.15M Buy
23,946
+509
+2% +$217K ﹤0.01% 2464
2022
Q4 		$8.05M Buy
23,437
+1,216
+5% +$294K ﹤0.01% 2402
2022
Q3 		$4.2M Buy
22,221
+740
+3% +$172K ﹤0.01% 2762
2022
Q2 		$4.54M Buy
21,481
+2,007
+10% +$422K ﹤0.01% 2750
2022
Q1 		$6.51M Buy
19,474
+643
+3% +$186K ﹤0.01% 2635
2021
Q4 		$6.13M Buy
18,831
+266
+1% +$114K ﹤0.01% 2772
2021
Q3 		$9.02M Buy
18,565
+1,264
+7% +$556K ﹤0.01% 2525
2021
Q2 		$8.04M Buy
17,301
+1,511
+10% +$824K ﹤0.01% 2619
2021
Q1 		$10.9M Buy
15,790
+1,775
+13% +$1.43M ﹤0.01% 2300
2020
Q4 		$10.4M Buy
14,015
+1,130
+9% +$880K ﹤0.01% 2155
2020
Q3 		$8.94M Buy
12,885
+2,798
+28% +$2.1M ﹤0.01% 2009
2020
Q2 		$8.55M Buy
10,087
+1,613
+19% +$1.05M ﹤0.01% 2016
2020
Q1 		$3.03M Buy
8,474
+3,524
+71% +$1.27M ﹤0.01% 2436
2019
Q4 		$1.16M Buy
4,950
+1,081
+28% +$109K ﹤0.01% 3228
2019
Q3 		$435K Buy
3,869
+91
+2% +$14.4K ﹤0.01% 3515
2019
Q2 		$662K Buy
3,778
+2,194
+139% +$372K ﹤0.01% 3366
2019
Q1 		$250K Buy
+1,584
New +$195K ﹤0.01% 3669

Other funds holding BTAI

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management's BTAI Position: Q1 2026 in Review

Geode Capital Management increased its BioXcel Therapeutics (BTAI) stake by 12% in Q1 2026, buying an estimated $39.5K and bringing the position to 230,168 shares worth $309K. The position accounts for ﹤0.01% of the portfolio, ranked #3765.

Geode Capital Management first reported a position in BTAI in Q1 2019 and has held it in 29 quarters since. The position peaked at $10.9M in Q1 2021. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

  • Geode Capital Management held 230,168 shares of BioXcel Therapeutics worth $309K as of Q1 2026.
  • Geode Capital Management bought 24,000 BioXcel Therapeutics shares in Q1 2026, an estimated $39.5K.
  • BioXcel Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3765 holding.
  • Geode Capital Management first reported a position in BioXcel Therapeutics in Q1 2019 and has held it in 29 quarters since.
  • Geode Capital Management's BioXcel Therapeutics position peaked at $10.9M in Q1 2021.
  • 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.